Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for patients suffering from chronic pain.
With a substantial number of patients suffering from chronic pain being denied access to current therapies due to societal issues surrounding prescription drug abuse and misuse, Collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the Company’s proprietary DETERx® technology platform.
DETERx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. The DETERx technology platform is covered by U.S. and international patents and patent applications. Collegium’s lead product candidate, Xtampza ER™, is an abuse-deterrent, extended-release, oral formulation of oxycodone, and is the first of a number of product candidates using the DETERx technology. Xtampza ER has received Fast Track designation from the U.S. Food and Drug Administration (FDA).